Indication, mechanism of action, pharmacokinetics, dosage form, route of administration, and storage conditions of sargramostim (leukine™)?

Indication: Sargramostim (Leukine™) is indicated for the treatment of certain types of cancer, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), as well as for the treatment of bone marrow transplant failure or engraftment delay.

Mechanism of action: Sargramostim is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) that stimulates the production of white blood cells in the bone marrow.

Pharmacokinetics: Sargramostim is administered by injection and has a half-life of approximately 2 hours. It is primarily eliminated through the kidneys.

Dosage form: Sargramostim is available as a sterile lyophilized powder for injection.

Route of administration: Sargramostim is typically administered by subcutaneous injection or intravenous infusion.

Storage conditions: Sargramostim should be stored at room temperature (20-25°C or 68-77°F) and protected from light. Once reconstituted, the solution should be used immediately or stored in the refrigerator at 2-8°C (36-46°F) for up to 24 hours.

Indication:

- Treatment of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy.

Mechanism of Action:

- Sargramostim is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) that stimulates the bone marrow to produce neutrophils.

Pharmacokinetics:

- Half-life: 2-3 hours
- Metabolized: In the liver and kidneys
- Excreted: In the urine (70%) and feces (30%)

Dosage Form and Route of Administration:

- Injection solution
- Subcutaneous or intravenous injection

Dosage:

- 250 mcg/m2/day subcutaneously or intravenously infused over 2 hours

Storage Conditions:

- Refrigerate at 2-8°C (36-46°F)
- Protect from light